Indication Mitigare (colchicine) 0.6 mg capsules are indicated for prophylaxis of gout flares in adults. The safety and effectiveness of Mitigare for

Transcription

1

2 2 Indication Mitigare (colchicine) 0.6 mg capsules are indicated for prophylaxis of gout flares in adults. The safety and effectiveness of Mitigare for acute treatment of gout flares during prophylaxis have not been studied. Mitigare is not an analgesic medication and should not be used to treat pain from other causes.

3 Introduce your patients to Mitigare (colchicine) an affordable option to help adults prevent gout flares. Request free samples today at mitigare.com/trueblue. Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. Patients with both renal and hepatic impairment should not be given Mitigare. 3

4 True. And blue. FDA-approved Mitigare and its authorized generic colchicine 0.6 mg capsules deliver the benefits of this time-tested treatment for gout flare prevention. Distinctive two-tone blue capsules provide a pop of color to help patients identify this medication from their other prescribed daily medications. 1 Mitigare Hikma International Pharmaceuticals LLC 10 Lisinopril Lupin Pharmaceuticals, Inc. 227 Metformin Alkem Laboratories, Ltd. 122 Atorvastatin Dr. Reddy s Laboratories, Ltd Atenolol Sandoz 3571 Hydrochlorothiazide Qualitest Pharmaceuticals 70 Lovastatin Sandoz Please see Important Safety Information on back and accompanying Full Prescribing Information and Medication Guide. 1. White Paper What Is the Significance of the Color of a Pill. Wallcur, LLC. Accessed June 28, 2016.

5 80 % of 150 surveyed pharmacists believed visual similarities in pills contributed to trouble identifying medications. 2 Fatal overdoses have been reported with colchicine in adults and children. Keep Mitigare out of the reach of children. 2. Survey Shows Pharmacists Believe Distinctive Tablet Appearance Reduces Dispensing and Patient Medication Errors. Colorcon. Retrieved from 07/31/346248/102806/en/Survey-Shows-Pharmacists-Believe- Distinctive-Tablet-Appearance-Reduces-Dispensing-and-Patient- Medication-Errors.html. Published July 31, Accessed June 28, 2016.

6 Seeing blue may lead to saving green. Colchicine has been a natural gout flare prevention medication for centuries and today West-Ward Pharmaceuticals offers an affordable option with authorized generic 0.6 mg capsules. Colchicine no longer has to be expensive. When you prescribe Mitigare 0.6 mg capsules, eligible patients have the potential to save on the authorized generic as well as through the Mitigare True Blue Savings program. For all eligible patients 18 years or older who are legal residents of the United States or Puerto Rico. Please see for more details on eligibility requirements. Colchicine 0.6 mg History 3 Sales Volume 187 Sales Increase, Volume Decreases by 33% Sales $709M Volume (Tabs/Caps in millions) Sept 2010 Generic Colchicine Marketing Ends Sept 2014 Mitigare Granted FDA Approval Sept 2009 Colcrys Launch June 2012 Takeda Acquires Colcrys Jan 2015 Mitigare AG Launches Please see Important Safety Information on back and accompanying Full Prescribing Information and Medication Guide. 3. IMS National Perspective Data

7 Find the bright choice. Offer your adult patients access to an effective, affordable option Mitigare and its authorized generic. 5 CO-PAY COUPONS, PI, AND MEDGUIDE TO BE INSERTED IN POCKET First 30 days $ Free 5 * * Lorem ipsum dolor sit amet, consectetur refills adipiscing elit. Nunc tempus tristique dignissim. Seeing Nunc blue cursus may lead nisl to non bibendum ultricies. saving Nulla green viverra with velit Mitigare sed ipsum ornare True tempor. Blue Savings. Suspendisse ut diam tellus. Duis tristique, leo in convallis viverra, velit Patient/Caregiver: urna Give euismod this card to lacus, your pharmacist nec sodales along with odio a valid prescription for the authorized generic lectus colchicine vel est. 0.6 mg Cum capsules, sociis or the natoque brand Mitigare (colchicine) 0.6 mg capsules. penatibus et magnis dis parturient montes, Valid on the authorized generic colchicine 0.6 mg nascetur capsules ridiculus (NDC ), mus. Proin or the posuere, brand Mitigare mauris hendrerit (NDC ). Please refer to faucibus commodo, the back of this card for the program requirements quam and restrictions. libero lacinia lectus, in facilisis justo magna Pharmacist: et nunc. In pretium ex sed turpis Submit claim to MedImpact using the detailed luctus processing ullamcorper. information below. Etiam Processor vitae ipsum. requires Valid Prescription ID #, Patient Name, PCN #, and DOB for claim adjudication. Please refer to the back of this card for the program requirements and restrictions. Activation required prior Activation to presenting required. it to the pharmacy with your prescription. Cards can be activated by visiting Go to or by calling or call to activate your card Request No prior matter to presenting your coverage, free it to contact the pharmacy us to better understand with your prescription. how best afford your medication. samples today at mitigare.com/trueblue. MedImpact RxBIN#: XXXXXX MedImpact PCN/Carrier/Group#: RxBIN#: XXXXX PCN/Carrier/Group#: Identification#: XXXXXX Identification#: Person Code#: XXXX XX Person Expiration Code#: Date: 01 XX/XX/XXXX Expiration Date: 06/30/2017 *Maximum savings of $65 on first fill, $50 on refills. Must meet eligibility requirements. See reverse side. *Maximum savings of $65 on first fill, $50 on refills. Must meet eligibility requirements. See reverse side.

8 Important Safety Information Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. Patients with both renal and hepatic impairment should not be given Mitigare. Fatal overdoses have been reported with colchicine in adults and children. Keep Mitigare out of the reach of children. Blood dyscrasias such as myelosuppression, leukopenia, granulocytopenia, thrombocytopenia and aplastic anemia have been reported with colchicine used in therapeutic doses. Monitor for toxicity and, if present, consider temporary interruption or discontinuation of colchicine. Drug interaction with dual P-gp and CYP3A4 inhibitors: Co-administration of colchicine with dual P-gp and CYP3A4 inhibitors has resulted in lifethreatening interactions and death. Neuromuscular toxicity and rhabdomyolysis may occur with chronic treatment with colchicine in therapeutic doses, especially in combination with other drugs known to cause this effect. Patients with impaired renal function and elderly patients (including those with normal renal and hepatic function) are at increased risk. Consider temporary interruption or discontinuation of Mitigare. The most commonly reported adverse reactions with colchicine are gastrointestinal symptoms, including diarrhea, nausea, vomiting and abdominal pain. Indication Mitigare is indicated for prophylaxis of gout flares in adults. The safety and effectiveness of Mitigare for acute treatment of gout flares during prophylaxis have not been studied. Mitigare is not an analgesic medication and should not be used to treat pain from other causes. Please see accompanying Full Prescribing Information and Medication Guide. Visit for more information. Manufactured by: West-Ward Pharmaceuticals Corp., Eatontown, NJ Mitigare is a registered trademark of West-Ward Pharmaceuticals Corp. All product names and trademarks that appear herein are the property of their respective owners West-Ward Pharmaceuticals Corp. All rights reserved. For U.S. Health Care Professionals Only. WW00261